港股医药外包概念股集体上攻昭衍新药涨超8%

Core Viewpoint - The Hong Kong pharmaceutical outsourcing sector experienced a collective surge, with notable increases in stock prices for companies such as Kanglong Chemical, Zhaoyan New Drug, WuXi Biologics, and others following a regulatory announcement from the National Medical Products Administration [1] Group 1: Market Reaction - Pharmaceutical outsourcing stocks in Hong Kong saw significant gains, with Kanglong Chemical rising over 9%, Zhaoyan New Drug increasing over 8%, WuXi Biologics and Kelaiying both up over 4%, and Tigermed up over 2% [1] - The market's positive response is attributed to the announcement that clinical trial applications for innovative drugs will be reviewed within 30 working days if they meet certain criteria [1] Group 2: Regulatory Changes - The National Medical Products Administration announced that it will complete the review and approval of clinical trial applications for qualifying innovative drugs within 30 working days from the date of acceptance, effective immediately [1] - The announcement specifies that the review applies to traditional Chinese medicine, chemical drugs, and biological products that meet at least one of three criteria [1] Group 3: External Concerns - There are ongoing market concerns regarding the U.S. administrative draft, particularly the "Biological Safety Act," which has undergone 10 changes since the end of 2023 [1] - The stock price reactions of representative CXO companies indicate a gradual response to the developments related to the "Biological Safety Act" [1]